Results of a large phase 3 study show that secukinumab does not offer any advantage over abatacept for patients with active rheumatoid arthritis (RA) who lack or have a suboptimal response to tumor necrosis factor (TNF) inhibitors (Blanco FJ, et al. Arthritis Rheumatol. Feb 19, 2017. Epub ahead of print). Secukinumab was more effective than placebo, but on a variety of measures of efficacy, responses to abatacept were numerically higher than those to secukinumab. The lack of a benefit over abatacept led to premature closing of the trial.
In a recent interview with Value-Based Care in Rheumatology, Clifton O. Bingham III, MD, Associate Professor of Medicine, Division of Rheumatology, and Director of the Johns Hopkins Arthritis Center, discussed current trends in rheumatology and the pillars of care at Johns Hopkins.
In a recent interview, Eric L. Matteson, MD, Chair of the Division of Rheumatology at Mayo Clinic, Rochester, MN, and Professor of Medicine, discussed the Division of Rheumatology. The staff consists of 18 rheumatologists, including 2 pediatric rheumatologists or joint pediatric-adult rheumatologists. It also includes several mid-level providers, including nurse practitioners, physician assistants, and nurses.
Results 1 - 3 of 3